Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | DRD3 | P35462 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.70 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.70 |
| ▸ | HTR3B | O95264 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.70 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.70 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437345 | 1.00 | ADRA2A (0.70) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL5925589 | 0.99 | RAB9A (0.71) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL20348311 | 0.91 | ADRA2A (0.70) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL22022353 | 0.89 | ADRA2A (0.67) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL5925629 | 0.88 | ADRA2A (0.73) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL5925617 | 0.87 | RAB9A (0.73) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL18618398 | 0.87 | ADRA2A (0.71) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL17068310 | 0.87 | ADRA2A (0.65) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL17068281 | 0.86 | ADRA2A (0.64) | ADRA2ACYP2D6DRD3LMNACYP1A2 | |
| SCHEMBL20348394 | 0.86 | ADRA2A (0.64) | ADRA2ACYP2D6DRD3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-02-27 | — | — | US | claimed |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2021-09-30 | — | — | US | claimed |
| EP-3837008-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | claimed |
| CN-112703036-A | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2021-04-23 | — | — | CN | claimed |
| WO-2020035555-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | claimed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| EP-3837008-B1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-09-24 | — | — | EP | disclosed |
| CN-112703036-B | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2025-02-27 | — | — | US | disclosed |
| US-11717500-B2 | Treatment of spondyloarthritis | PHARMACYL AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210236441-A1 | TREATMENT OF SPONDYLOARTHRITIS | PHARMACYL AB (SE) | 2021-08-05 | — | — | US | disclosed |
| EP-3837008-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | Pharmacyl AB (SE) | 2021-06-23 | — | — | EP | disclosed |
| CN-112703036-A | Substituted benzamides and their use in therapy | 法玛西尔有限公司 | 2021-04-23 | — | — | CN | disclosed |
| WO-2020035555-A2 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | PHARMACYL AB (SE) | 2020-02-20 | — | — | WO | disclosed |
| US-20150258190-A1 | NICOTINAMIDE AS ADJUVANT | NOVARTIS AG (CH) | 2015-09-17 | — | — | US | disclosed |
| WO-2014064229-A1 | NICOTINAMIDE AS ADJUVANT | NOVARTIS AG (CH) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064761-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | ADRA2A 2822/4885CYP2D6 687/4885DRD3 3812/4885 |
| US-11717500-B2 | Treatment of spondyloarthritis | SPAST, IL17A, SLC10A2 | ADRA2A 3027/4885CYP2D6 1637/4885DRD3 3549/4885 |
| US-20210236441-A1 | TREATMENT OF SPONDYLOARTHRITIS | SPAST, IL17A, SLC10A2 | ADRA2A 3027/4885CYP2D6 1637/4885DRD3 3549/4885 |
| US-20210299071-A1 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | BRD4, SI, BRD7 | ADRA2A 2822/4885CYP2D6 687/4885DRD3 3812/4885 |
| US-20150258190-A1 | NICOTINAMIDE AS ADJUVANT | NAMPT, NNT, NQO1 | ADRA2A 1412/4885CYP2D6 3047/4885DRD3 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.